Prevalence and distribution of Plasmodium vivax Duffy Binding Protein gene duplications in Sudan

Safaa Ahmed; Kareen Pestana; Anthony Ford; Mohammed Elfaki; Eiman Gamil; Arwa F. Elamin; Samuel Omer Hamad; Tarig Mohamed Elfaki; Sumaia Mohamed Ahmed Abukashawa; Eugenia Lo; Muzamil M. Abdel Hamid

doi:10.1371/journal.pone.0287668

Abstract

Plasmodium vivax Duffy Binding Protein (PvDBP) is essential for interacting with Duffy antigen receptor for chemokines (DARC) on the surface of red blood cells to allow invasion. Earlier whole genome sequence analyses provided evidence for the duplications of PvDBP. It is unclear whether PvDBP duplications play a role in recent increase of P. vivax in Sudan and in Duffy-negative individuals. In this study, the prevalence and type of PvDBP duplications, and its relationship to demographic and clinical features were investigated. A total of 200 malaria-suspected blood samples were collected from health facilities in Khartoum, River Nile, and Al-Obied. Among them, 145 were confirmed to be P. vivax, and 43 (29.7%) had more than one PvDBP copies with up to four copies being detected. Both the Malagasy and Cambodian types of PvDBP duplication were detected. No significant difference was observed between the two types of duplications between Duffy groups. Parasitemia was significantly higher in samples with the Malagasy-type than those without duplications. No significant difference was observed in PvDBP duplication prevalence and copy number among study sites. The functional significance of PvDBP duplications, especially those Malagasy-type that associated with higher parasitemia, merit further investigations.

Citation: Ahmed S, Pestana K, Ford A, Elfaki M, Gamil E, Elamin AF, et al. (2023) Prevalence and distribution of Plasmodium vivax Duffy Binding Protein gene duplications in Sudan. PLoS ONE 18(7): e0287668. https://doi.org/10.1371/journal.pone.0287668

Editor: Luzia H. Carvalho, Fundação Oswaldo Cruz Centro de Pesquisas René Rachou: Fundacao Oswaldo Cruz Instituto Rene Rachou, BRAZIL

Received: October 19, 2022; Accepted: June 12, 2023; Published: July 20, 2023

This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Data Availability: All relevant data are within the manuscript and its Supporting Information files.

Funding: The author(s) received no specific funding for this work

Competing interests: Authors declare that no competing interests exist.

Introduction

Malaria is a significant public health problem in Sudan and almost 75% of the population is at risk of malaria. Plasmodium vivax is one of the prominent malarial parasites in Sudan that can cause severe infection and substantial morbidity. Plasmodium vivax and P. vivax/P. falciparum co-infection are responsible for 11% and 9.1% of total malaria cases, respectively, in Sudan [1–3]. The emergence and marked increase of P. vivax poses new challenges to malarial treatment and control in the country. P. vivax was previously less common in Sub-Saharan African countries [1]. However, in recent years, the number of P. vivax cases has markedly increased across Africa with increasing proportions of severe cases, and infections spreading to new areas where Duffy-negative individuals are predominant [4–10].

The pathology of P. vivax infection depends critically on the parasite’s ability to recognize and invade human erythrocytes, and multiply leading to clinical signs or symptoms [11]. While P. falciparum uses a complex array of receptors to invade human erythrocytes, P. vivax merozoites completely depend on the interactions between P. vivax Duffy Binding Protein (PvDBP) and the Duffy antigen receptor for chemokines (DARC) expressed on the surface of human erythrocytes [12–15]. Duffy-negative individuals who have low expression of DARC were previously thought to be resistant to P. vivax infections [16], but the essentiality of the PvDBP-DARC interaction for P. vivax invasion has been recently challenged [17]. Over the past five years, there has been an increasing number of reports on Duffy-negative individuals being infected with P. vivax throughout Africa and in South America [6, 18–21]. This changing epidemiology is a serious public health problem as the majority of African populations are Duffy-negatives [21, 22]. The genetic characteristics of PvDBP would provide a deeper understanding of the biological mechanisms behind erythrocyte invasion and the functional consequences of PvDBP variation [11]. PvDBP was previously described as a single copy gene [18], but recent whole genome sequences from field isolates provided evidence for the duplications of this gene [11, 16]. Parasites with two distinct types of PvDBP duplications are circulating globally, namely the Malagasy and the Cambodian duplications based on the where they were first described [11]. The high prevalence of PvDBP duplications raises the possibility that this structural change could be linked to the ability of P. vivax to infect Duffy-negative individuals [6]. Mutations in PvDBP in P. vivax from Duffy-negative Ethiopians did not lead to binding to Duffy-negative erythrocytes in vitro [21]. Other possible alternative mechanisms of erythrocyte invasion are via PvDBP gene duplications that allow evasion of host immune responses [23] or via a Duffy-independent pathway that involves the interactions between PvRBP2b and Transferrin receptor 1 [24].

Parasites with multiple PvDBP copies have been shown to influence host immune evasion [23]. Increased PvDBP copy number may lead to increased mRNA levels and confer protection to P. vivax in vitro against invasion inhibition by human monoclonal antibodies targeting region II of PvDBP [23]. However, the extent of invasion inhibition could also be dependent of PvDBP sequence polymorphisms and/or Duffy status of host individuals. In Africa, PvDBP duplications have been reported in Ethiopia and Madagascar, but such phenomenon is not yet clear in Sudan. Therefore, this study investigated the prevalence and type of PvDBP gene duplication, as well as its relationship with demographic and clinical features among P. vivax cases in Sudan. Findings would allow comparisons of the distribution and prevalence of PvDBP duplications with other African P. vivax isolates.

Methodology

Ethics statement

Ethical clearance was obtained from Khartoum State Ministry of Health, Sudan (number KMOH-REC-062.2). Verbal informed consent was obtained from each participant and guardians of minor prior to their participation in the study.

Sample collection and processing

A cross sectional study was conducted between May 2018 to January 2021 in hospitals and health facilities in urban and rural Khartoum including the Gezira Slang and Alsarorab clinics, River Nile (Northern Sudan) and Al-Obied (Central Sudan). These study sites have similar malaria incidence and low-moderate transmission [25]. A total of 200 whole blood samples from suspected P. vivax patients (24 from Khartoum, 53 from Gezira Slang, 44 from Alsarorab, 55 from River Nile, and 24 from Al Obeid) were collected in EDTA tubes. P. vivax was diagnosed by microscopic examination of Giemsa-stained thin and thick blood films and/or rapid diagnosis test (SD Bioline, Standard Diagnostics Inc., South Korea). Demographical and clinical data including age, gender, ethnicity, and medical history were recorded with questionnaire. Patients who were infected with other Plasmodium species (P. falciparum, P. malariae, P. ovale and/or mixed infection) were excluded from this study. Genomic DNA was extracted from venous blood or dried blood spots (Whatman 3mm filter paper) using ZymoBead Genomic DNA kit (Zymo Research) following the manufacturer’s procedures [6]. The concentrations of DNA were determined using a Nanodrop spectrophotometer (UV1visible Nanodrop 1000, Thermo Fisher) prior to PCR. The obtained DNA concentration ranged from 150–700 ng/μl.

Identification of P. vivax by nested and quantitative PCR

Nested PCR was performed in a total volume of 20μl including maxime PCR premix (intron biotechnology, Inc, South Korea), 2.5U i-Taq DNA polymerase, 2.5μM dNTPs, 2μl DNA template, 0.5μl from each primer (10pmol/μl), and 17μl deionized H2O. Species-specific primers that amplify the 18S rRNA amplicon were used to detect P. vivax as previously described [26]. The first round of PCR condition was as follow: initial denaturation 94°C for 2 minutes, followed by 40 cycles of: denaturation 94°C for 30 seconds, annealing 55°C for 1 minute, extension 72°C for 1 minute and final extension 72°C for 5 minutes. The second round of PCR was as follow: initial denaturation 94°C for 2 minutes, followed by 40 cycles of: denaturation 94°C for 30 seconds, annealing 58°C for 1 minute, extension 72°C for 1 minute and a final extension 72°C for 5 minutes. Negative and positive controls were included in each PCR.

In addition to PCR, the SYBR Green qPCR method that amplifies a segment of the 18S rRNA genes of P. vivax [27], was used to quantify parasite density of the samples. Amplification was performed in a 20μL reaction containing 10μL of 2x SYBR Green qPCR Master Mix (Thermo Scientific), 0.5 μM of primer (forward: 5’AGAATTTTCTCTTCGGAGTTTATTCTTAGATTGCT-3’; reverse: 5’GCCGCAAGCTCCACGCCTGGTGGTGC-3’), and 1μL of genomic DNA. PCR conditions were as follow: initial denaturation of 95°C for 3 minutes, followed by 45 cycles of: denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, extension at 68°C for 1 minute immediately followed by 95°C hold step for 10 seconds and a final melting curve step with temperatures increasing from 65°C to 95°C in 0.5°C increments. Each assay included a positive plasmid control for the 18S rRNA P. vivax gene (MRA-178; BEI Resources) to ensure primer specificity in addition to negative controls. A ten-fold dilution series was used to estimate the standard curve and thus amplification efficiency. Patient samples which yielded Ct values higher than 40 were considered negative. P. vivax parasitemia was calculated with the following equation: Parasite DNA (per/μL) = [2^{E×(40−Ctsample)}/10]; where Ct is the threshold cycle of the individual sample and E is the amplification efficiency [28].

Duffy blood group genotyping

All P. vivax positive samples were included in Duffy blood group genotyping based on TaqMan qPCR assays. The primers (forward: 5’GGCCTGAGGCTTGTGCAGGCAG-3’; reverse: 5’ CATACTCACCCTGTGCAGACAG-3’) and dye-labeled probes (FAM: CCTTGGCTCTTA[C]CTTGGAAGCACAGG-BHQ; HEX: CCTTGGCTCTTA[T]CTTGGAAGCACAGG-BHQ) amplified the GATA1 transcription factor-binding site of the DARC gene promoter. Amplification was performed in a 20μL reaction containing 7μL TaqMan Fast Advanced Master mix (Thermo Scientific), 0.5 μM of forward and reverse primers, 0.5 μM of each of the dye-labeled probes, and 1μL of DNA template. PCR conditions were as follows: initial denaturation of 95°C for 2 minutes, followed by 45 cycles of: denaturation at 95°C for 3 seconds and annealing at 58°C for 30 seconds. The fluorescent signals emitted by the dye-labeled probes provided the data for allelic discrimination and determination of the Duffy genotype. The DARC gene from a subset of Duffy-positive (C/T and T/T) and all Duffy-negative (C/C) individuals were amplified and sequenced to confirm the genotyping results.

Detection of PvDBP duplications

Five separated amplifications were conducted using published primers designed to detect the different types of PvDBP duplications. They included primers as positive controls (BF/BR, AF/AR and AF2/AR2), primers specific for the Malagasy duplication (BF/AR), and primers specific for the Cambodian duplication (BF/AR2) (Table 1).

Download:

Table 1. Information of primers used for PCR and qPCR detection of PvDBP duplications based on previous study [11].

https://doi.org/10.1371/journal.pone.0287668.t001

In addition, PvDBP copy number was measured with the SYBR Green qPCR method. The P. vivax aldolase gene, which is known to be a single copy gene, was used as an internal reference to calculate the copy number of PvDBP. The primers for PvDBP duplications amplified between region II and region III of PvDBP [6]. Amplification was performed in a 20μL reaction containing 10μL of 2x SYBR Green qPCR Master Mix (Thermo Scientific), 0.5 μM of forward and reverse primers (Table 1), and 1μL of genomic DNA that was standardized to ~50 genomes/μL. PCR conditions were as follow: initial denaturation of 95°C for 3 minutes, followed by 40 cycles of: denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds, extension at 68°C for 1 minute immediately followed by 65°C hold step for 5 seconds and a final melting curve step with temperatures increasing from 65°C to 95°C in 0.5°C increments. Each assay included a positive plasmid control for PvDBP and Pv adolase (known to be single copy) along with negative controls. Samples were run in triplicate and the average Ct values for Pv aldolase (Ct_Pvaldo) and PvDBP (Ct_PvDBP) were calculated for each sample. Ct_{Pvaldo cal} and Ct_{PvDBP cal} were the average difference between Ct_Pvaldo and Ct_PvDBP obtained from the positive control that contained a single copy of Pv aldolase and PvDBP gene fragments. Quantification of PvDBP duplication was calculated based on the equation from previous studies [6, 29, 30], as follow: N = 2^ΔΔCt±SD, where ΔΔCt = (Ct_Pvaldolase- Ct_PvDBP)-(Ct_{PvAldolase cal}-Ct_{PvDBP cal}). The standard deviation was calculated to be used for the calibrator with the following equation: SD = √(S²_pvdbp+S²_pvaldo+S²_cal). For each sample, the assessment of PvDBP copy number was repeated twice for validation.

Statistical analyses

The normality of data was tested using the Shapiro-Wilk test. For data that departed from normality, nonparametric methods were used for pairwise comparison among groups. All potential significance of differences in parasitemia levels among age groups (under 5 years old, 5–12 years old, and above 12 years old), Duffy groups (C/T, T/T and C/C), as well as infections with and without PvDBP duplications were assessed using a one-way non-parametric Kruskal-Wallis test. For each categorical variable (age, Duffy group, and PvDBP duplications), we employed a non-parametric multiple comparison procedure using Dunn’s test with the Benjamini-Hochberg adjustment to control for false discovery rate. A p-value of 0.05 was used to determine significance between groups.

Results

Characteristics of the study populations

The age of study participants ranged from 3 months to 70 years old (mean = 21 years old). Males represented 60.2% and females represented 39.8% of the study participants. Patients displayed malaria symptoms including fever, headache, vomiting, fatigue, chills, and abdominal pain. All malaria-infected individuals were microscopic-positive and had parasitemia based on microscopy ranged from 182–38,400 (average 6,863±5,911) parasites per microliter of blood. A significant difference was detected in parasitemia levels across age groups. Individuals above 12 years old showed a significantly lower parasitemia than those under 5 years old (p = 0.001) as well as those aged 5–12 (p = 0.005; Fig 1A).

Download:

Fig 1.

Comparisons of parasitemia levels among (A) age groups; (B) Duffy genotypes; and (C) PvDBP duplication types based on PCR analysis.

https://doi.org/10.1371/journal.pone.0287668.g001

Of the 200 samples, 145 were confirmed to be P. vivax, of which 134 were monoinfection and 11 were coinfected with P. falciparum (S1 File). Based on Duffy genotyping and DARC gene sequencing, among these 145 P. vivax-infected patients, 127 (87.6%) were heterozygous Duffy-positive (C/T), 15 (10.3%) were homozygous Duffy-positive (T/T), and 3 (2.1%) were homozygous Duffy-negative (C/C). Heterozygous Duffy-positive (C/T) individuals were the most prevalent. Significant differences were found in parasitemia levels between the Duffy-positive and Duffy-negative groups. The parasitemia was significantly lower in the Duffy-negatives (C/C) than the homozygous Duffy-positive (T/T; p = 0.002) and heterozygous Duffy-positive (C/T; p = 0.001; Fig 1B), despite small samples of Duffy negatives. No significant difference was detected in parasitemia between the homozygous and heterozygous Duffy-positives (p>0.05). More samples are needed in future study to draw confident comparisons.

Frequency of PvDBP duplications among Duffy groups and study sites

Of the 145 P. vivax-infected samples, 43 (29.7%) were detected with more than one copies of PvDBP based on PCR analysis. For these 43 samples with multiple PvDBP copies, both the Malagasy and the Cambodian types of PvDBP duplication were detected (Fig 2). Samples with the Malagasy-type duplications yielded a 612bp band and those with the Cambodian-type duplications yielded a 736bp band, respectively, using primers BF/AR and BF/AR2 (Fig 2). Three out of the 43 samples with more than one copies of PvDBP were observed in P. vivax and P. falciparum coinfected samples and the rest were P. vivax monoinfection.

Download:

Fig 2. Gel identification of PvDBP duplication types of three selected P. vivax-infected samples based on PCR assays.

The three positive controls (AF/AF, BF/BR, and AF2/AR2) showed approximately 650bp band, while no bands in the negative controls. Sample (1) indicated Malagasy-type duplication with 613bp band; sample (2) indicated Cambodian-type duplication with 736bp band; and sample (3) indicated a single copy of the PvDBP gene with no duplication.

https://doi.org/10.1371/journal.pone.0287668.g002

Of the 43 P. vivax samples detected with multiple PvDBP copies, 23 (53.5%) have the Cambodian-type and 20 (46.5%) had the Malagasy-type PvDBP duplication based on PCR analysis. Approximately 30% of the homozygous and heterozygous Duffy-positives had multiple PvDBP copies. The frequency of PvDBP duplication was not significantly different between heterozygous (C/T; 36/127 = 28.3%) and homozygous Duffy-positives (T/T; 5/15 = 33.3%) (p = 0.19; Table 2). However, only 2 out of the 3 Duffy-negatives (66%) had multiple PvDBP copies, and the number of Duffy-negative samples was too small to draw any confident comparisons. For all three Duffy groups, nearly half of the samples with multiple PvDBP copies had the Cambodian-type duplications and the other half had the Malagasy-type duplications (Table 2). No significant difference was observed between the two types of duplications among Duffy groups (p = 0.29; Table 2).

Download:

Table 2. Prevalence of PvDBP duplications in Duffy-positives (C/T and T/T) and Duffy-negative (C/C) individuals (N = 145) based on PCR analysis.

https://doi.org/10.1371/journal.pone.0287668.t002

The parasitemia was significantly higher in samples with the Malagasy-type duplication than those with no duplication (p = 0.002; Fig 1C). No significant difference was observed in parasitemia between samples with the Cambodian- and Malagasy-type duplications as well as samples with the Cambodian-type and those without duplication (Fig 1C). When stratified by age group, samples with the Malagasy-type duplications have significantly higher parasitemia than the single-copy ones for individuals of age under 5 and over 12 years old (S1 Fig). No significant difference was observed in parasitemia between samples with Cambodian duplication type and those with Malagasy-type or no-duplication. No samples under 5 years old were detected with the Cambodian-type duplications (S1 Fig).

No significant difference was detected in the frequency of PvDBP duplications among study sites based on PCR analysis (Table 3). About 36% (13/36) of the P. vivax samples in Alsarorab, 33% (6/18) in El Obeid, 30% (11/37) in Gezira Slang, 33% (2/6) in Khartoum, and 23% (11/48) in River Nile were shown with multiple PvDBP copies. Based on qPCR analysis, most of the samples with PvDBP duplications had 2–3 gene copies (Fig 3). For examples, in Alsarorab, 25% of the samples had 2–3 PvDBP copies and 5.6% had 4 copies or higher. In El Obeid, 16.7% and 5.5% had 2–3 copy and 4 or higher copies, respectively. In Gezira Slang, 16.2% and 13.5% had 2–3 copy and 4 or higher copies. In River Nile, 16.7% and 8.35% had 2–3 copy and 4 or higher copies, respectively. By contrast, in Khartoum, all samples with PvDBP duplications (33.3%) had 2–3 copies (Fig 3). Both the Malagasy- and the Cambodian-type duplications were detected in each of the study sites (Table 3). The estimations of PvDBP duplications by PCR were, for most part, consistent with the estimations by qPCR, with the exception of three samples that showed Cambodian/Malagasy-type duplications by PCR but a single-copy by qPCR and four samples that showed high copies by qPCR but no duplication by PCR.

Download:

Fig 3. Distribution of single and multiple PvDBP copy parasites among the five study sites in Sudan based on qPCR analysis.

https://doi.org/10.1371/journal.pone.0287668.g003

Download:

Table 3. Prevalence of single and multiple PvDBP duplications among the five study sites in Sudan based on PCR analysis.

https://doi.org/10.1371/journal.pone.0287668.t003

Discussion

Malarial parasite genomes are highly variable, containing mutations ranging from simple small changes in DNA sequences to complex large-scale changes in gene structure such as the number of copies of individual genes [11]. These genetic changes allow the parasites to adapt to and/or evade the human immune system and successfully transmit from one to another individual. Information on the structure of genes that involve in red blood cell invasion provides clues for the pathways and mechanisms of parasite invasion. PvDBP plays a key role in erythrocyte invasion by P. vivax and duplications of this gene might influence the efficiency of the invasion process [11, 31]. This study investigated the prevalence and characteristics of PvDBP gene duplications in the Sudanese P. vivax.

PvDBP duplications occurred in ~30% of the Sudanese P. vivax. Both the Malagasy- and the Cambodian-type duplications were detected in the isolates. To our knowledge, this is the first report on the presence of the Cambodian-type PvDBP duplication in the Sudanese P. vivax. Previous study indicated only the presence of Malagasy-type duplication in Sudan with a relatively low frequency (4/32; 12.5%) [16]. A broader coverage of study areas and larger sample size in this study, as well as the use of specific primer sets that target the Cambodian- and Malagasy-type PvDBP duplications may explain such discrepancy. The frequency of the PvDBP duplication observed in this study was consistent with a previous study conducted in Cambodia (29%) [11], but lower than that reported in Madagascar (52.9%) [16] and Ethiopia (65.5%) [6]. Given that the same two types of PvDBP duplications have been observed among P. vivax clinical isolates from Ethiopia and Madagascar [31], it is not surprising that P. vivax parasites carrying these duplications have been circulating widely in East Africa [11]. Although the urban and rural areas of Khartoum as well as areas in Northern and Central Sudan are similar in P. vivax malaria incidence and transmission intensity [25], the PvDBP duplication prevalence was fairly similar among study sites. The discrepancy in PvDBP duplications observed in seven samples between PCR and qPCR may be explained by the presence of duplications other than the Cambodian- or Malagasy-type detected by the published primers. Alternatively, mutations at the priming sites may also result in inaccurate assessment of copy number by qPCR. Our ongoing analyses of whole genome sequences from the Sudanese P. vivax will provide confirmations to these predictions.

The significantly lower parasitemia observed in individuals over 12 years old compared to other age groups was consistent with earlier studies that younger children are less immune to plasmodial infections [32]. Previous studies showed that the parasite densities were not significantly different between parasites with one or two PvDBP copies nor between the two types of PvDBP duplications [6, 11]. Nevertheless, we found higher parasitemia in infections with the Malagasy- and Cambodian-type duplications, though the later one is not significantly different from those with no duplication. Such difference prevails when parasitemia was stratified by age group, indicating that age is unlikely a confounding factor for the comparisons. Given only limited samples were detected with Malagasy- or Cambodian-type duplication, future study should expand broader samples to verify these findings. Individuals infected with P. vivax parasites carrying multiple copies of PvDBP have been shown with high levels of anti-DBPII antibody [23]. PvDBP gene amplification leads to increased mRNA levels, and thus it is plausible that high-copies PvDBP allows more production of PvDBP proteins that confer to stronger binding with DARC and thus better invasion efficiency than with single-copy parasites [31]. Parasites with high-copies PvDBP may also well mediate immune evasion mechanism to enhance erythrocyte invasion [23]. Given only 43 samples were detected with PvDBP duplications, the association of parasitemia with duplication types needs to be further verified with larger samples.

Among the P. vivax infected samples, heterozygous Duffy-positive (C/T) individuals were the most prevalent, consistent with previous findings [33]. By contrast, the prevalence of Duffy-negative (C/C) individuals (2.1%) was much lower than that reported in Abdelraheem et al. (4/48 = 8.3%) [2] and Albsheer et al. (34/190 = 17.9%) [33] in Sudan. Individuals of the three Duffy genotypes were also significantly different in parasitemia, with the highest found in heterozygous Duffy-positives (C/T) and lowest in the Duffy-negatives (C/C). We are currently expanding the number of Duffy-negative samples for copy number assays with the goal to draw confident comparisons with Duffy-positive ones as shown in this study. Low parasitemia in the Duffy-negative individuals has been documented previously [19, 27, 33], and this finding supports the notion that P. vivax invasion to human red blood cells is reduced with little to no Duffy antigen expression.

Because of the high adaptability of Plasmodium species, PvDBP duplications within the parasite genome was likely evolved in response to variations in human Duffy blood group across malaria-endemic settings [31]. The frequency of PvDBP duplication was not significantly different between heterozygous Duffy positives (C/T) and homozygous Duffy-positive (T/T), consistent with earlier studies that found no significant difference in the prevalence of PvDBP duplications by Duffy genotypes [13, 21, 27]. Previous study on the Ethiopian P. vivax showed that the proportion of parasites with PvDBP duplications was higher in individuals carrying the FY*A allele than those carrying the FY*B one [27]. PvDBP duplications could be a mechanism that increases recognition and/or binding to erythrocytes expressing the FY*A allele through increasing the amount of PvDBP protein on the surface of the merozoites. Though the number of Duffy-negative samples in this study is very small, this result was consistent with an earlier study in Ethiopia where two-third of these infections had PvDBP duplications [27]. Arguably, PvDBP duplications may not be selected in response to Duffy negativity [29] nor there is a specific sequence polymorphism in PvDBP associates with Duffy-negative erythrocyte invasion [34]. PvDBP duplications are much more widespread and complex, and the polymorphic nature of PvDBP certainly allows P. vivax to colonize diverse ecological niches as well as to evade host immune system. Recent studies have shown that PvDBP duplications allow P. vivax to evade host anti-PvDBP humoral immunity [23], reassuring PvDBP region II as a promising candidate for a blood-stage vaccine against P. vivax; but whether such structural change influences the PvDBP vaccine efficiency and/or facilitates binding to the weakly expressed DARC on Duffy-negative reticulocytes remain unclear. Further studies are needed to clarify the functional role of PvDBP duplications in Duffy-negative erythrocyte invasion.

To conclude, findings of this study allow comparisons of the distribution and prevalence of PvDBP duplications with other African P. vivax isolates. The origin and functional significance of the Cambodian- and Malagasy-type PvDBP duplications merit further investigations. Future study should expand sampling of Duffy-negative infected individuals to test the association between PvDBP duplication and Duffy genotypes. It is necessary to determine if PvDBP duplication (in relative to single-copy PvDBP) is associated with a significant increase in the levels of PvDBP protein expression. More importantly, future studies will be needed to determine if PvDBP duplications enable this protein to interact with different invasion receptors on the human RBC surface.

Supporting information

S1 File. Information of samples included in this study and PvDBP duplication estimations by PCR and qPCR assays.

https://doi.org/10.1371/journal.pone.0287668.s001

(XLSX)

S2 File. The result of seven P. vivax-infected samples which showed discrepancy result between PCR and qPCR.

Gel images of PvDBP duplication types of these samples based on PCR were included.

https://doi.org/10.1371/journal.pone.0287668.s002

(XLSX)

S1 Fig. Comparisons of parasitemia levels across PvDBP duplication types stratified by age groups based on PCR analysis.

https://doi.org/10.1371/journal.pone.0287668.s003

(PDF)

S2 Fig. Gel identification of PvDBP duplication types of seven P. vivax-infected samples that showed discrepancy result between PCR and qPCR.

(A) A 613bp band observed in samples 124, 162, 167 and 168 using the duplication primer BF/AR for Malagasy-type duplication and a 736bp band in samples 18, 55, 99, 133 and 143 using primer BF/AR2 for Cambodian-type duplication. No bands were shown in the negative controls. (B) A ~650bp band observed in all samples using the controls primers AF/AR and AF2/AR2. No bands were shown in the negative controls. (C) A 650bp band observed in all samples using the controls primer BF/BR. No bands were shown in the negative controls.

https://doi.org/10.1371/journal.pone.0287668.s004

(PDF)

S1 Raw images.

https://doi.org/10.1371/journal.pone.0287668.s005

(PDF)

Acknowledgments

Authors are grateful for the enrolled participants in all study areas for their participation in this study. M.M.A.H, S.A and E.L kindly provided all materials and consumables for the study.

References

1. Howes RE, Reiner RC Jr., Battle KE, Longbottom J, Mappin B, Ordanovich D, et al. Plasmodium vivax transmission in Africa. PLos Negl Trop Dis. 2015;9(11):e0004222. pmid:26587988
- View Article
- PubMed/NCBI
- Google Scholar
2. Abdelraheem MH, Albsheer MM, Mohamed HS, Amin M, Mahdi Abdel Hamid M. Transmission of Plasmodium vivax in Duffy-negative individuals in central Sudan. Trans R Soc Trop Med Hyg. 2016;110(4):258–60. pmid:27076512
- View Article
- PubMed/NCBI
- Google Scholar
3. world malaria report 2021.
4. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22(5):430–5. pmid:19571748
- View Article
- PubMed/NCBI
- Google Scholar
5. Anstey NM, Russell B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends Parasitol. 2009;25(5):220–7. pmid:19349210
- View Article
- PubMed/NCBI
- Google Scholar
6. Lo E, Hostetler JB, Yewhalaw D, Pearson RD, Hamid MMA, Gunalan K, et al. Frequent expansion of Plasmodium vivax Duffy binding protein in Ethiopia and its epidemiological significance. PLos Negl Trop Dis. 2019;13(9):e0007222. pmid:31509523
- View Article
- PubMed/NCBI
- Google Scholar
7. Niang M, Sane R, Sow A, Sadio BD, Chy S, Legrand E, et al. Asymptomatic Plasmodium vivax infections among Duffy-negative population in Kedougou, Senegal. Trop Med Health. 2018;46:45.
- View Article
- Google Scholar
8. Oboh MA, Singh US, Ndiaye D, Badiane AS, Ali NA, Bharti PK, et al. Presence of additional Plasmodium vivax malaria in Duffy negative individuals from Southwestern Nigeria. Malaria Journal. 2020;19(1):229. pmid:32590997
- View Article
- PubMed/NCBI
- Google Scholar
9. Gunalan K, Niangaly A, Thera MA, Doumbo OK, Miller LH. Plasmodium vivax infections of Duffy-negative erythrocytes: Historically undetected or a recent adaptation? Trends Parasitol. 2018;34(5):420–9. pmid:29530446
- View Article
- PubMed/NCBI
- Google Scholar
10. Poirier P, Doderer-Lang C, Atchade PS, Lemoine J-P, de l’Isle M-LC, Abou-bacar A, et al. The hide and seek of Plasmodium vivax in West Africa: report from a large-scale study in Beninese asymptomatic subjects. Malaria Journal. 2016;15(1):570. pmid:27887647
- View Article
- PubMed/NCBI
- Google Scholar
11. Hostetler JB, Lo E, Kanjee U, Amaratunga C, Suon S, Sreng S, et al. Independent origin and global distribution of distinct Plasmodium vivax Duffy binding protein gene duplications. PLos Negl Trop Dis. 2016;10(10):e0005091. pmid:27798646
- View Article
- PubMed/NCBI
- Google Scholar
12. Fang XD, Kaslow DC, Adams JH, Miller LH. Cloning of the Plasmodium vivax Duffy receptor. Mol Biochem Parasitol. 1991;44(1):125–32. pmid:1849231
- View Article
- PubMed/NCBI
- Google Scholar
13. Batchelor JD, Zahm JA, Tolia NH. Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC. Nat Struct Mol Biol. 2011;18(8):908–14. pmid:21743458
- View Article
- PubMed/NCBI
- Google Scholar
14. Batchelor JD, Malpede BM, Omattage NS, DeKoster GT, Henzler-Wildman KA, Tolia NH. Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC. PLos Pathog. 2014;10(1):e1003869. pmid:24415938
- View Article
- PubMed/NCBI
- Google Scholar
15. Weiss GE, Crabb BS, Gilson PR. Overlaying molecular and temporal aspects of malaria parasite invasion. Trends Parasitol. 2016;32(4):284–95. pmid:26778295
- View Article
- PubMed/NCBI
- Google Scholar
16. Menard D, Chan ER, Benedet C, Ratsimbasoa A, Kim S, Chim P, et al. Whole genome sequencing of field isolates reveals a common duplication of the Duffy binding protein gene in Malagasy Plasmodium vivax strains. PLos Negl Trop Dis. 2013;7(11):e2489. pmid:24278487
- View Article
- PubMed/NCBI
- Google Scholar
17. Menard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, et al. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci U S A. 2010;107(13):5967–71. pmid:20231434
- View Article
- PubMed/NCBI
- Google Scholar
18. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature. 2008;455(7214):757–63. pmid:18843361
- View Article
- PubMed/NCBI
- Google Scholar
19. Lo E, Russo G, Pestana K, Kepple D, Abagero BR, Dongho GBD, et al. Contrasting epidemiology and genetic variation of Plasmodium vivax infecting Duffy-negative individuals across Africa. Int J Infect Dis. 2021;108:63–71. pmid:33991680
- View Article
- PubMed/NCBI
- Google Scholar
20. Zimmerman PA. Plasmodium vivax infection in Duffy-negative people in Africa. Am J Trop Med Hyg. 2017;97(3):636–8. pmid:28990906
- View Article
- PubMed/NCBI
- Google Scholar
21. Gunalan K, Lo E, Hostetler JB, Yewhalaw D, Mu J, Neafsey DE, et al. Role of Plasmodium vivax Duffy-binding protein 1 in invasion of Duffy-null Africans. Proc Natl Acad Sci U S A. 2016;113(22):6271–6. pmid:27190089
- View Article
- PubMed/NCBI
- Google Scholar
22. Twohig KA, Pfeffer DA, Baird JK, Price RN, Zimmerman PA, Hay SI, et al. Growing evidence of Plasmodium vivax across malaria-endemic Africa. PLos Negl Trop Dis. 2019;13(1):e0007140. pmid:30703083
- View Article
- PubMed/NCBI
- Google Scholar
23. Popovici J, Roesch C, Carias LL, Khim N, Kim S, Vantaux A, et al. Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity. Nat Commun. 2020;11(1):953. pmid:32075983
- View Article
- PubMed/NCBI
- Google Scholar
24. Gruszczyk J, Kanjee U, Chan LJ, Menant S, Malleret B, Lim NTY, et al. Transferrin receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax. Science. 2018;359(6371):48–55. pmid:29302006
- View Article
- PubMed/NCBI
- Google Scholar
25. Elagali A, Ahmed A, Makki N, Ismail H, Ajak M, Alene KA, et al. Spatiotemporal mapping of malaria incidence in Sudan using routine surveillance data. Scientific Reports. 2022;12(1):1–13.
- View Article
- Google Scholar
26. Snounou G. Detection and identification of the four malaria parasite species infecting humans by PCR amplification. Methods Mol Biol. 1996;50:263–91. pmid:8751365
- View Article
- PubMed/NCBI
- Google Scholar
27. Lo E, Yewhalaw D, Zhong D, Zemene E, Degefa T, Tushune K, et al. Molecular epidemiology of Plasmodium vivax and Plasmodium falciparum malaria among Duffy-positive and Duffy-negative populations in Ethiopia. Malar J. 2015;14:84. pmid:25884875
- View Article
- PubMed/NCBI
- Google Scholar
28. Murphy SC, Prentice JL, Williamson K, Wallis CK, Fang FC, Fried M, et al. Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials. Am J Trop Med Hyg. 2012;86(3):383–94. pmid:22403305
- View Article
- PubMed/NCBI
- Google Scholar
29. Roesch C, Popovici J, Bin S, Run V, Kim S, Ramboarina S, et al. Genetic diversity in two Plasmodium vivax protein ligands for reticulocyte invasion. PLos Negl Trop Dis. 2018;12(10):e0006555. pmid:30346980
- View Article
- PubMed/NCBI
- Google Scholar
30. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, et al. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLos One. 2007;2(10):e1089. pmid:17971853
- View Article
- PubMed/NCBI
- Google Scholar
31. Golassa L, Amenga-Etego L, Lo E, Amambua-Ngwa A. The biology of unconventional invasion of Duffy-negative reticulocytes by Plasmodium vivax and its implication in malaria epidemiology and public health. Malar J. 2020;19(1):299. pmid:32831093
- View Article
- PubMed/NCBI
- Google Scholar
32. Koepfli C, Robinson LJ, Rarau P, Salib M, Sambale N, Wampfler R, et al. Blood-stage parasitaemia and age determine plasmodium falciparum and P. vivax gametocytaemia in Papua New Guinea. PLos One. 2015;10(5):e0126747. pmid:25996916
- View Article
- PubMed/NCBI
- Google Scholar
33. Ali Albsheer MM, Hussien A, Kwiatkowski D, Hamid MMA, Ibrahim ME. The Duffy T-33C is an insightful marker of human history and admixture. Meta Gene. 2020;26:100782. pmid:32837914
- View Article
- PubMed/NCBI
- Google Scholar
34. Hoque MR, Elfaki MMA, Ahmed MA, Lee S-K, Muh F, Ali Albsheer MM, et al. Diversity pattern of Duffy binding protein sequence among Duffy-negatives and Duffy-positives in Sudan. Malaria Journal. 2018;17(1):297. pmid:30119671
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. Howes RE, Reiner RC Jr., Battle KE, Longbottom J, Mappin B, Ordanovich D, et al. Plasmodium vivax transmission in Africa. PLos Negl Trop Dis. 2015;9(11):e0004222. pmid:26587988
View Article
PubMed/NCBI
Google Scholar

[2] View Article

[3] PubMed/NCBI

[4] Google Scholar

[ref2] 2. Abdelraheem MH, Albsheer MM, Mohamed HS, Amin M, Mahdi Abdel Hamid M. Transmission of Plasmodium vivax in Duffy-negative individuals in central Sudan. Trans R Soc Trop Med Hyg. 2016;110(4):258–60. pmid:27076512
View Article
PubMed/NCBI
Google Scholar

[6] View Article

[7] PubMed/NCBI

[8] Google Scholar

[ref3] 3. world malaria report 2021.

[ref4] 4. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22(5):430–5. pmid:19571748
View Article
PubMed/NCBI
Google Scholar

[11] View Article

[12] PubMed/NCBI

[13] Google Scholar

[ref5] 5. Anstey NM, Russell B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends Parasitol. 2009;25(5):220–7. pmid:19349210
View Article
PubMed/NCBI
Google Scholar

[15] View Article

[16] PubMed/NCBI

[17] Google Scholar

[ref6] 6. Lo E, Hostetler JB, Yewhalaw D, Pearson RD, Hamid MMA, Gunalan K, et al. Frequent expansion of Plasmodium vivax Duffy binding protein in Ethiopia and its epidemiological significance. PLos Negl Trop Dis. 2019;13(9):e0007222. pmid:31509523
View Article
PubMed/NCBI
Google Scholar

[19] View Article

[20] PubMed/NCBI

[21] Google Scholar

[ref7] 7. Niang M, Sane R, Sow A, Sadio BD, Chy S, Legrand E, et al. Asymptomatic Plasmodium vivax infections among Duffy-negative population in Kedougou, Senegal. Trop Med Health. 2018;46:45.
View Article
Google Scholar

[23] View Article

[24] Google Scholar

[ref8] 8. Oboh MA, Singh US, Ndiaye D, Badiane AS, Ali NA, Bharti PK, et al. Presence of additional Plasmodium vivax malaria in Duffy negative individuals from Southwestern Nigeria. Malaria Journal. 2020;19(1):229. pmid:32590997
View Article
PubMed/NCBI
Google Scholar

[26] View Article

[27] PubMed/NCBI

[28] Google Scholar

[ref9] 9. Gunalan K, Niangaly A, Thera MA, Doumbo OK, Miller LH. Plasmodium vivax infections of Duffy-negative erythrocytes: Historically undetected or a recent adaptation? Trends Parasitol. 2018;34(5):420–9. pmid:29530446
View Article
PubMed/NCBI
Google Scholar

[30] View Article

[31] PubMed/NCBI

[32] Google Scholar

[ref10] 10. Poirier P, Doderer-Lang C, Atchade PS, Lemoine J-P, de l’Isle M-LC, Abou-bacar A, et al. The hide and seek of Plasmodium vivax in West Africa: report from a large-scale study in Beninese asymptomatic subjects. Malaria Journal. 2016;15(1):570. pmid:27887647
View Article
PubMed/NCBI
Google Scholar

[34] View Article

[35] PubMed/NCBI

[36] Google Scholar

[ref11] 11. Hostetler JB, Lo E, Kanjee U, Amaratunga C, Suon S, Sreng S, et al. Independent origin and global distribution of distinct Plasmodium vivax Duffy binding protein gene duplications. PLos Negl Trop Dis. 2016;10(10):e0005091. pmid:27798646
View Article
PubMed/NCBI
Google Scholar

[38] View Article

[39] PubMed/NCBI

[40] Google Scholar

[ref12] 12. Fang XD, Kaslow DC, Adams JH, Miller LH. Cloning of the Plasmodium vivax Duffy receptor. Mol Biochem Parasitol. 1991;44(1):125–32. pmid:1849231
View Article
PubMed/NCBI
Google Scholar

[42] View Article

[43] PubMed/NCBI

[44] Google Scholar

[ref13] 13. Batchelor JD, Zahm JA, Tolia NH. Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC. Nat Struct Mol Biol. 2011;18(8):908–14. pmid:21743458
View Article
PubMed/NCBI
Google Scholar

[46] View Article

[47] PubMed/NCBI

[48] Google Scholar

[ref14] 14. Batchelor JD, Malpede BM, Omattage NS, DeKoster GT, Henzler-Wildman KA, Tolia NH. Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC. PLos Pathog. 2014;10(1):e1003869. pmid:24415938
View Article
PubMed/NCBI
Google Scholar

[50] View Article

[51] PubMed/NCBI

[52] Google Scholar

[ref15] 15. Weiss GE, Crabb BS, Gilson PR. Overlaying molecular and temporal aspects of malaria parasite invasion. Trends Parasitol. 2016;32(4):284–95. pmid:26778295
View Article
PubMed/NCBI
Google Scholar

[54] View Article

[55] PubMed/NCBI

[56] Google Scholar

[ref16] 16. Menard D, Chan ER, Benedet C, Ratsimbasoa A, Kim S, Chim P, et al. Whole genome sequencing of field isolates reveals a common duplication of the Duffy binding protein gene in Malagasy Plasmodium vivax strains. PLos Negl Trop Dis. 2013;7(11):e2489. pmid:24278487
View Article
PubMed/NCBI
Google Scholar

[58] View Article

[59] PubMed/NCBI

[60] Google Scholar

[ref17] 17. Menard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, et al. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci U S A. 2010;107(13):5967–71. pmid:20231434
View Article
PubMed/NCBI
Google Scholar

[62] View Article

[63] PubMed/NCBI

[64] Google Scholar

[ref18] 18. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature. 2008;455(7214):757–63. pmid:18843361
View Article
PubMed/NCBI
Google Scholar

[66] View Article

[67] PubMed/NCBI

[68] Google Scholar

[ref19] 19. Lo E, Russo G, Pestana K, Kepple D, Abagero BR, Dongho GBD, et al. Contrasting epidemiology and genetic variation of Plasmodium vivax infecting Duffy-negative individuals across Africa. Int J Infect Dis. 2021;108:63–71. pmid:33991680
View Article
PubMed/NCBI
Google Scholar

[70] View Article

[71] PubMed/NCBI

[72] Google Scholar

[ref20] 20. Zimmerman PA. Plasmodium vivax infection in Duffy-negative people in Africa. Am J Trop Med Hyg. 2017;97(3):636–8. pmid:28990906
View Article
PubMed/NCBI
Google Scholar

[74] View Article

[75] PubMed/NCBI

[76] Google Scholar

[ref21] 21. Gunalan K, Lo E, Hostetler JB, Yewhalaw D, Mu J, Neafsey DE, et al. Role of Plasmodium vivax Duffy-binding protein 1 in invasion of Duffy-null Africans. Proc Natl Acad Sci U S A. 2016;113(22):6271–6. pmid:27190089
View Article
PubMed/NCBI
Google Scholar

[78] View Article

[79] PubMed/NCBI

[80] Google Scholar

[ref22] 22. Twohig KA, Pfeffer DA, Baird JK, Price RN, Zimmerman PA, Hay SI, et al. Growing evidence of Plasmodium vivax across malaria-endemic Africa. PLos Negl Trop Dis. 2019;13(1):e0007140. pmid:30703083
View Article
PubMed/NCBI
Google Scholar

[82] View Article

[83] PubMed/NCBI

[84] Google Scholar

[ref23] 23. Popovici J, Roesch C, Carias LL, Khim N, Kim S, Vantaux A, et al. Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity. Nat Commun. 2020;11(1):953. pmid:32075983
View Article
PubMed/NCBI
Google Scholar

[86] View Article

[87] PubMed/NCBI

[88] Google Scholar

[ref24] 24. Gruszczyk J, Kanjee U, Chan LJ, Menant S, Malleret B, Lim NTY, et al. Transferrin receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax. Science. 2018;359(6371):48–55. pmid:29302006
View Article
PubMed/NCBI
Google Scholar

[90] View Article

[91] PubMed/NCBI

[92] Google Scholar

[ref25] 25. Elagali A, Ahmed A, Makki N, Ismail H, Ajak M, Alene KA, et al. Spatiotemporal mapping of malaria incidence in Sudan using routine surveillance data. Scientific Reports. 2022;12(1):1–13.
View Article
Google Scholar

[94] View Article

[95] Google Scholar

[ref26] 26. Snounou G. Detection and identification of the four malaria parasite species infecting humans by PCR amplification. Methods Mol Biol. 1996;50:263–91. pmid:8751365
View Article
PubMed/NCBI
Google Scholar

[97] View Article

[98] PubMed/NCBI

[99] Google Scholar

[ref27] 27. Lo E, Yewhalaw D, Zhong D, Zemene E, Degefa T, Tushune K, et al. Molecular epidemiology of Plasmodium vivax and Plasmodium falciparum malaria among Duffy-positive and Duffy-negative populations in Ethiopia. Malar J. 2015;14:84. pmid:25884875
View Article
PubMed/NCBI
Google Scholar

[101] View Article

[102] PubMed/NCBI

[103] Google Scholar

[ref28] 28. Murphy SC, Prentice JL, Williamson K, Wallis CK, Fang FC, Fried M, et al. Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials. Am J Trop Med Hyg. 2012;86(3):383–94. pmid:22403305
View Article
PubMed/NCBI
Google Scholar

[105] View Article

[106] PubMed/NCBI

[107] Google Scholar

[ref29] 29. Roesch C, Popovici J, Bin S, Run V, Kim S, Ramboarina S, et al. Genetic diversity in two Plasmodium vivax protein ligands for reticulocyte invasion. PLos Negl Trop Dis. 2018;12(10):e0006555. pmid:30346980
View Article
PubMed/NCBI
Google Scholar

[109] View Article

[110] PubMed/NCBI

[111] Google Scholar

[ref30] 30. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, et al. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLos One. 2007;2(10):e1089. pmid:17971853
View Article
PubMed/NCBI
Google Scholar

[113] View Article

[114] PubMed/NCBI

[115] Google Scholar

[ref31] 31. Golassa L, Amenga-Etego L, Lo E, Amambua-Ngwa A. The biology of unconventional invasion of Duffy-negative reticulocytes by Plasmodium vivax and its implication in malaria epidemiology and public health. Malar J. 2020;19(1):299. pmid:32831093
View Article
PubMed/NCBI
Google Scholar

[117] View Article

[118] PubMed/NCBI

[119] Google Scholar

[ref32] 32. Koepfli C, Robinson LJ, Rarau P, Salib M, Sambale N, Wampfler R, et al. Blood-stage parasitaemia and age determine plasmodium falciparum and P. vivax gametocytaemia in Papua New Guinea. PLos One. 2015;10(5):e0126747. pmid:25996916
View Article
PubMed/NCBI
Google Scholar

[121] View Article

[122] PubMed/NCBI

[123] Google Scholar

[ref33] 33. Ali Albsheer MM, Hussien A, Kwiatkowski D, Hamid MMA, Ibrahim ME. The Duffy T-33C is an insightful marker of human history and admixture. Meta Gene. 2020;26:100782. pmid:32837914
View Article
PubMed/NCBI
Google Scholar

[125] View Article

[126] PubMed/NCBI

[127] Google Scholar

[ref34] 34. Hoque MR, Elfaki MMA, Ahmed MA, Lee S-K, Muh F, Ali Albsheer MM, et al. Diversity pattern of Duffy binding protein sequence among Duffy-negatives and Duffy-positives in Sudan. Malaria Journal. 2018;17(1):297. pmid:30119671
View Article
PubMed/NCBI
Google Scholar

[129] View Article

[130] PubMed/NCBI

[131] Google Scholar

Figures

Abstract

Introduction

Methodology

Ethics statement

Sample collection and processing

Identification of P. vivax by nested and quantitative PCR

Duffy blood group genotyping

Detection of PvDBP duplications

Statistical analyses

Results

Characteristics of the study populations

Frequency of PvDBP duplications among Duffy groups and study sites

Discussion

Supporting information

S1 File. Information of samples included in this study and PvDBP duplication estimations by PCR and qPCR assays.

S2 File. The result of seven P. vivax-infected samples which showed discrepancy result between PCR and qPCR.

S1 Fig. Comparisons of parasitemia levels across PvDBP duplication types stratified by age groups based on PCR analysis.

S2 Fig. Gel identification of PvDBP duplication types of seven P. vivax-infected samples that showed discrepancy result between PCR and qPCR.

S1 Raw images.

Acknowledgments

References